A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha

EPS101-10-02 is a Phase Ib open label, multicentre clinical trial comprising of a Dose Escalation phase (Part 1) followed by a Dose Expansion phase (Part 2) of MOv18 IgE in patients with folate receptor alpha-expressing (5% or higher) platinum resistant ovarian cancer The dose escalation part of the study will primarily assess the safety and tolerability of MOv18 IgE in ascending dose cohorts, until the determination of the maximum tolerated dose (MTD) or maximum administered dose (MAD). Part 2 (dose expansion) will further assess the safety, tolerability and anti-tumour activity of MOv18 Ig

Trial Details

NCT ID

NCT06547840

Phase

PHASE1

Sponsor

Epsilogen Ltd

Status

RECRUITING

Cancer Type

Triple Negative (TNBC) Breast Cancer

Interventions

MOv18 IgE

Locations (sample)

Bristol, United Kingdom|51.45523,-2.59665
Edinburgh, United Kingdom|55.95206,-3.19648
Leeds, United Kingdom|53.79648,-1.54785
London, United Kingdom|51.50853,-0.12574
London, United Kingdom|51.50853,-0.12574

Key Eligibility Criteria

Patients must meet all of the following criteria:
Female ≥18 years of age.
Written (signed and dated) informed consent.
Histologically or cytologically confirmed advanced, recurrent or metastatic ovarian cancer, endometrial cancer, triple-negative breast cancer i. Ov…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →